June 09, 2015
Nutra Pharma has announced that they have entered into a strategic collaboration with Nationwide Laboratory Services, Inc. in which Nationwide occupies a portion of Nutra Pharma's production facility in Plantation Florida, sharing their regulatory personnel and capacities with Nutra Pharma.
June 9, 2015 -- Coral Springs, Florida -- Nutra Pharma Corporation (OTC: NPHC), a biotechnology company marketing Nyloxin and Pet Pain-Away in the over-the-counter (OTC) pain management market, and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that they have entered into a facility and personnel sharing agreement with Nationwide Laboratory Services, Inc.
“We are very pleased to be sharing our resources with Nationwide Laboratory Services," stated Rik J. Deitsch, Chairman and CEO of Nutra Pharma Corporation. “Nationwide's expertise in structuring and conducting clinical trials represents tremendous value for Nutra Pharma's future endeavors in the development of orphan drugs. Nationwide has high caliber regulatory, quality control and quality assurance personnel who will be very helpful to Nutra Pharma as we grow our business and scope of products,” he concluded.
Nationwide Laboratory Services, Inc. operates as a clinical diagnostics laboratory, performing routine and specialty human diagnostics. The company also offers clinical trial services, such as specimen and special handling requirements, status of test results, turnaround time, testing, participants test results, channeling calls to technical or professional personnel, communicating specimen issues, notifying investigational site of critical calls, and telephone support with data management training services; and courier tracking services.
“We are very happy to be working with Nutra Pharma,” commented Mark I. Delahunty, Chairman and CEO of Nationwide Laboratory Services, Inc. "Our collaboration with Nutra Pharma is more synergistic than it may appear on the surface. Our businesses dovetail quite nicely from a facilities standpoint, helping to optimize the use of space and personnel," he concluded.
About Nutra Pharma Corp.
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. Additionally, the Company markets drug products for sale for the treatment of pain under the brand Nyloxin® and Pet Pain-Away.
For additional information about Nutra Pharma, visit:
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The collaboration with Nationwide Laboratories should not be construed as an indication in any way whatsoever of the future value of the Company’s common stock or its financial value. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.